Mountain Crest Acquisition Corp. V (MCAG)
| Market Cap | 33.95M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | 83,015 |
| Shares Out | 3.17M |
| EPS (ttm) | -0.24 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,241 |
| Open | 10.77 |
| Previous Close | 10.71 |
| Day's Range | 10.71 - 10.91 |
| 52-Week Range | 10.47 - 11.10 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About MCAG
Mountain Crest Acquisition Corp. V does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company intends to pursue target business opportunities in North America and the Asia Pacific region. Mountain Crest Acquisition Corp. V was incorporated in 2021 and is based in New York, New York. Mountain Crest Acquisition Corp. V operates as a subsidiary of Mountain Crest Global Holdings LLC. [Read more]
Financial Performance
Financial StatementsNews
Mountain Crest Acquisition Corp. V Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Annual Report on Form 10-K and Quarterly Report on Form 10-Q
NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Mountain Crest Acquisition Corp. V (NASDAQ: MCAG, the “Company”) today announced that it received an expected deficiency notification letter from the Listin...
Mountain Crest Acquisition Corp. V Announces Listing Transfer to the Nasdaq Capital Market
NEW YORK, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Mountain Crest Acquisition Corp. V (Nasdaq: MCAG) (the “Company”) announced today that it has received approval from the Nasdaq Stock Market (“Nasdaq”) to t...
AUM Biosciences, a Global Biotechnology Company Developing Precision Oncology Therapeutics, Announces Plans to Become a Public Company via Merger with Mountain Crest Acquisition Corp. V
SINGAPORE and NEW YORK, Oct. 20, 2022 (GLOBE NEWSWIRE) -- AUM Biosciences Pte. Ltd. (“AUM”), a clinical-stage biotechnology company, advancing a clinical stage pipeline designed to deploy multi-facete...
Mountain Crest Acquisition Corp. V Announces Closing of Fully-Exercised Over-Allotment Option in Connection with Its Initial Public Offering
NEW YORK, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Mountain Crest Acquisition Corp. V (NASDAQ: MCAGU, the “Company”) announced today that the underwriters in its initial public offering, pursuant to the term...
Mountain Crest Acquisition Corp. V Announces Closing of $60 Million Initial Public Offering
NEW YORK, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Mountain Crest Acquisition Corp. V (NASDAQ: MCAGU, the “Company”) announced today that it closed its initial public offering of 6,000,000 units at $10.00 pe...
Mountain Crest Acquisition Corp. V Announces Pricing of $60 Million Initial Public Offering
NEW YORK, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Mountain Crest Acquisition Corp. V (NASDAQ: MCAGU, the "Company") announced today that it priced its initial public offering of 6,000,000 units at $10.00 pe...